Stay updated on Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial page.

Latest updates to the Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial page
- Check7 days agoChange DetectedPage version updated from v3.4.3 to v3.5.0. This appears to be a technical update that does not change trial details or results.SummaryDifference0.0%

- Check14 days agoChange DetectedThe page now shows Revision: v3.4.3 and no longer lists Revision: v3.4.2.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe study locations have been expanded with multiple new sites worldwide, and the follow-up periods for overall survival and progression-free survival have been extended to up to 88 months, with several previously listed sites and shorter timeframes removed.SummaryDifference2%

- Check43 days agoChange DetectedA new revision tag, Revision: v3.4.2, was added to the page; the previous maintenance notice about a lapse in government funding and the Revision: v3.4.1 tag were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check50 days agoChange DetectedAdded a site-wide notice about potential delays due to a lapse in government funding and the NIH Clinical Center's operating status, and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.1%

- Check57 days agoChange DetectedUI and labeling updates include a glossary toggle and capitalization changes to QC-related text and revision/version notices. These changes do not affect the study content, eligibility criteria, or results.SummaryDifference0.1%

Stay in the know with updates to Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial page.